Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

AGM Results

30 Apr 2014 14:18

RNS Number : 9455F
Maven Income and Growth VCT 3 PLC
30 April 2014
 

 

Maven Income and Growth VCT 3 PLC (the Company) - Result of Annual General Meeting

 

At the Annual General Meeting of the Company held at 1-2 Royal Exchange Buildings, London EC3V 3LF at 10.00am on 30 April 2014, all of the Resolutions put to the Meeting were duly passed. In accordance with the provisions of D.2.2 of the Combined Code on Corporate Governance, the Company advises that for the Annual General Meeting, valid proxy appointments were made in respect of 4,418,229 shares and that the number of proxy votes lodged for each Resolution were as follows:

 

Resolutions

For

Discretion

Against

Withheld

Total

1

To receive the Annual Report and audited Financial Statements

4,168,510

201,640

5,940

42,139

4,418,229

2

To approve the Directors' Remuneration Report

3,943,634

201,640

162,878

110,077

4,418,229

3

To approve the Directors' remuneration policy for the three-year period ending 30 November 2016.

3,890,232

222,300

175,997

129,700

4,418,229

4

To approve a final dividend of 3.25p per ordinary share of 10p each in the capital of the Company (Ordinary Shares) for payment on 30 May 2014 to shareholders on the register at the close of business on 9 May 2014.

4,210,487

201,640

6,102

0

4,418,229

5

To re-elect Mr Michie as a Director

4,100,396

233,402

40,393

44,038

4,418,229

6

To re-elect Mr Nixon as a Director

4,103,242

235,821

38,885

40,281

 

4,418,229

7

To elect Mr Devani as a Director

4,087,110

230,751

33,127

67,241

4,418,229

8

To re-appoint Deloitte LLP as Auditor

 

3,850,813

275,153

242,300

49,963

4,418,229

9

To authorise the Directors to fix the remuneration of the Auditor

4,067,370

274,759

47,965

28,135

4,418,229

10

To authorise the Directors to allot new shares

4,075,578

262,554

41,789

38,308

4,418,229

11

To authorise disapplication of pre-emption rights

3,709,531

267,554

320,113

121,031

4,418,229

12

To authorise the Company to purchase its own shares

3,887,938

241,894

255,072

43,325

4,418,229

13

To allow a General Meeting to be called on not less than 14 days' notice

4,063,604

241,894

77,366

35,365

4,418,229

 

A vote withheld is not a vote in law and any such votes have not been included in the votes for or against the respective Resolutions. The voting figures will be available to view at: www.mavencp.com/migvct3.

 

Passing of Resolutions under Special Business

The Special Resolutions have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.//hemscott.com/nsm.do.

 

Issued on behalf of the Board

Maven Capital Partners UK LLP, Secretary

30 April 2014

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGIMMJTMBBJBRI
Date   Source Headline
20th May 202610:00 amRNSAdmission of Further Securities to Trading
15th May 202610:05 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:35 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20267:00 amRNSTransaction in Own Shares
30th Apr 20261:30 pmRNSResult of AGM
30th Apr 202610:54 amRNSAdmission of Further Securities to Trading
29th Apr 202612:28 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:19 amRNSAdmission of Further Securities to Trading
14th Apr 202611:07 amRNSIssue of Equity
8th Apr 20269:28 amRNSAdmission of Further Securities to Trading
25th Mar 202610:54 amRNSAdmission of Further Securities to Trading
24th Mar 20265:32 pmRNSAnnual Financial Report
24th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSNet Asset Value(s)
27th Feb 20265:01 pmRNSTransaction in Own Shares
27th Feb 20267:00 amRNSUnaudited NAV and Dividend Declaration
18th Feb 20264:52 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:05 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:00 amRNSDirector/PDMR Shareholding
17th Feb 202610:55 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:03 amRNSAdmission of Further Securities to Trading
16th Jan 20269:42 amRNSIssue of Equity
14th Jan 20262:35 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202510:20 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20254:47 pmRNSResult of General Meeting
28th Oct 20254:24 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:08 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:13 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:30 pmRNSHalf-year Report
22nd Jul 20254:49 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:46 pmRNSStatement re Unaudited NAV and Interim Dividend
15th May 20253:57 pmRNSTransaction in Own Shares
9th May 20259:54 amRNSDirector/PDMR Shareholding
9th May 20259:51 amRNSIssue of Equity
6th May 202511:53 amRNSIssue of Equity
2nd May 20251:11 pmRNSAudited NAV - Dividend Investment Scheme
1st May 20253:15 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:17 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.